FDA Panel Backs Novel Diabetes Pill From J&J

By Eric Volkman An advisory committee of the Food and Drug Administration has recommended approval for Johnson & Johnson‘s (NYSE: JNJ  ) next-generation diabetes treatment ...

JPMorgan Healthcare Conference Highlights: Questcor Pharmaceuticals

By Sean Williams The JPMorgan Healthcare Conference just finished up in San Francisco and was arguably the most important event of the entire year for the health care sector. This ...

J&J Failed to Warn of Vaginal Mesh Risks, Lawyer Says

By David Voreacos & Jef Feeley Johnson & Johnson (JNJ) sold a defective vaginal mesh implant after testing it inadequately and failing to warn of all the risks, a lawyer ...

Glaxo Future Hangs in Balance on 2013 U.S. Drug Approvals

By Albertina Torsoli & Makiko Kitamura It’s a make or break year for GlaxoSmithKline Plc. (GSK) The U.K.’s largest pharmaceutical company is counting on a spate of drugs ...

Novartis says Afinitor reduces tumors in rare genetic disease

* Phase III data in The Lancet show efficiency of drug * Afinitor already approved in U.S. and Europe for TSC (Reuters) – Novartis said its drug Afinitor helped reduce kidney ...

Good Chance For PharmAthene To Jump On Lucrative SIGA Litigation

By Jake King PharmAthene Inc. (PIP) announced on Thursday that the Delaware Supreme Court heard oral arguments in ongoing litigation with SIGA Technologies (SIGA). A previous ruling ...

Dendreon Rises on Optimism Over Cancer Drug Provenge

By Anna Edney Dendreon Corp. (DNDN) rose the most in a year on optimism that more patients will begin taking the biotechnology company’s prostate cancer drug Provenge. Dendreon ...

Sarepta May Seek Partnership Advice for Experimental Drug

By Sasha Damouni Sarepta Therapeutics Inc. (SRPT), a developer of an experimental drug for Duchenne muscular dystrophy, may seek advisers to find an overseas partner for the therapy, ...

10 Biotech Stocks With A History Of Beating Earning Expectations

By Kapitall The fourth quarter earnings season has just begun. Some companies manage to consistently surprise the market with positive earnings reports. If you believe that company ...

Will Qsymia’s Stellar Sales Growth Continue?

By Jordo Bivona Shares of Vivus (NASDAQ: VVUS) climbed on Monday after the company announced that prescriptions for its anti-obesity pill Qsymia had risen significantly in late ...

Celsion’s Phase III Blockbuster Data Revealed And It’s Been Right Underneath Your Nose – Part 2

By Alex Heisenberg Celsion (CLSN) is very close to its top-line release of its Phase III study, called the HEAT trial, designed to show that ThermoDox + RFA treatment improves the ...

Humira Will Help AbbVie Prevail, A Great Buy With Low Valuation

By Nick Chiu AbbVie is here to improve our lives as its name implies. “The beginning of the name connects the new company to Abbott and its heritage of pioneering science,” ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS